HPV self-testing has proven effective in boosting cervical cancer screening rates, according to a 2026 New Zealand study. The trial demonstrated non-inferiority and superiority over traditional Pap smears, particularly benefiting underscreened and marginalized groups.
The study, conducted in Northland, Aotearoa New Zealand, involved over 22,500 participants, with a mean age of 50, including more than 9,700 Māori individuals. In the intervention group, where HPV self-testing was universally offered, the screening rate reached 35.6%-significantly higher than the 24.9% in the control group receiving standard care.
Māori women, who are twice as likely to die from cervical cancer compared to non-Māori women, saw substantial improvements in screening rates. The study also noted increased participation from those who had never been screened or had not been screened in at least four years, as well as from individuals in medium or high deprivation areas.
Researchers recommend that countries with organized cervical cancer screening programs consider implementing HPV self-testing to enhance coverage and reduce preventable morbidity and mortality from cervical cancer.